# Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache

Source: https://onco.cc/trials/nct06961201/  
OnCo record `nct06961201` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase is a phase 3, randomised interventional study registered as NCT06961201 by Changchun GeneScience Pharmaceutical Co., Ltd., with a registry enrolment figure of 94 participants, started 2025-05-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension; standard treatment. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy. Primary outcome: The proportion of subjects with improved appetite based on A/CS-12 assessment; The proportion of subjects with a relative increase in BMI from baseline. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (according to the Veterans Administration Lung Study Group (VALG) staging system)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06961201
- Phase: 3
- Setting: A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer (ES-SCLC) in the Cachexia Phase
- Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT06961201: https://clinicaltrials.gov/study/NCT06961201

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- companies: [Changchun GeneScience Pharmaceutical](https://onco.cc/companies/changchun-genescience/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06961201.json